A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL

B-cell Acute Lymphoblastic Leukemia Clinical Trial

Official title:

A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04129099
• Other study ID #: PGC0006
• Status: Recruiting
• Phase: Early Phase 1
• Start date: October 22, 2019
• Est. completion date: June 2022

Study information

• Verified date: May 2020
• Source: Hebei Yanda Ludaopei Hospital
• Contact: Junfang Yang, Bachelor
• Phone: 13522084342
• Email: Yangjunfang77[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study is an early, open, single-centered trial. The aim of this study is to evaluate the safety and tolerance of GC022F CAR-T cell immunotherapy in relapsed or refractory B-ALL. The study will include 18 subjects to receive GC022F therapy.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 18
• Est. completion date: June 2022
• Est. primary completion date: September 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 2 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Aged 2-70 years;

2. Eastern cooperative oncology group (ECOG) performance status of 0 to 2;

3. Life expectancy=12 weeks;

4. CD19 and/or CD22 tumor expression demonstrated in bone marrow or peripheral blood by flow cytometry;

5. Relapsed or refractory B- ALL: a) Refractory B- ALL: MRD=0.1% or fail to achieve a CR after 2 cycles of a standard induction chemotherapy regimen or one-line/multi-line salvage chemotherapy; b) Relapsed B- ALL: Relapse after remission for the first time in 12 months or relapse after one-line/multi-line salvage chemotherapy; Relapse is defined as MRD=0.1% or recurrence of primitive cell in peripheral blood or bone marrow(>5%) after remission; c)Relapse after autologous stem cell transplantation or allogeneic hematopoietic stem cell transplantation; Relapse is defined as above; d)Patients with Philadelphia chromosome positive(Ph+) ALL were eligible if they were intolerant to or had failed two lines of tyrosine kinase inhibitor (TKI) therapy, or had t315i mutation.

6. Did not receive hematopoietic stem cell transplantation=6 months prior to enrollment;

7. Adequate organ function defined as: a) Creatinine clearance (as estimated by Cockcroft Gault) >60 mL/min; b) Serum ALT/AST <2.5 ULN; c) Total bilirubin <1.5 ULN (subjects with Gilbert's syndrome=3 ULN); d) Cardiac ejection fraction=50%, no evidence of clinically significant pericardial effusion as determined by an ECHO; e) No clinically significant pleural effusion; f) Baseline oxygen saturation >92% on room air;

8. Females of reproductive age must be in non-lactation period. Females of childbearing potential must have a negative serum or urine pregnancy test. All subjects must use medical-approved-contraception (such as intrauterine device and contraceptive drugs) during the period of trial and in 2 years after cell transfusion therapy; Males should avoid sperm donation;

9. Venous access can be established, peripheral blood mononuclear cells (PBMC) can be collected in researcher's judgement;

10. The subject agrees to and sign informed consent form, willing and able to comply with the planned visit, research, treatment planning, laboratory and other test procedures.

Exclusion Criteria:

1. Isolated extra-medullary disease relapse;

2. Central nervous system leukemia involved CNS-3;

3. Concomitant malignancy other than cured non-melanoma skin cancer or cervical carcinoma in situ or localized prostate cancer or superficial bladder cancer or ductal carcinoma in situ or diagnosis of other malignancy exceeds 5 years without relapse or treatment during the 5 years;

4. Any result of the following virology tests is positive: HIV; HCV; HBsAg; or HBCAb positive with HBV DNA copies positive; TPPA;

5. Live vaccine =4 weeks prior to enrollment;

6. For Ph+ ALL, TKI therapy =1 weeks prior to enrollment;

7. Presence of = grade 2 acute graft-versus-host disease (GVHD, Glucksberg criteria) or extensive chronic GVHD (Seattle criteria) that require treatment =4 weeks prior to enrollment, or during the study period the subject is required to receive anti- GCHD therapy in researcher's judgement;

8. Presence of concomitant disease that require systemic steroids or other immune suppressive therapy during the study period in researcher's judgement;

9. Allogeneic cell therapy (such as donor lymphocyte infusion, DLI) =4 weeks prior to enrollment;

10. CNS stereotactic radiotherapy =4 weeks prior to enrollment;

11. Toxicities related to previous therapy did not relieved to =1 grade, except hematological toxicity and alopecia;

12. Known life-threatening hypersensitivity to cyclophosphamide or fludarabine, or presence of other intolerant conditions, or severe allergic constitution;

13. Patients with active autoimmune disease (e.g., systemic lupus erythematosus, sjogren syndrome, rheumatoid arthritis, psoriasis, multiple sclerosis, inflammatory bowel disease, Hashimoto's thyroiditis, hypothyroidism which can be controlled by thyroid hormone replacement therapy is an exception);

14. For patients that underwent or plan to undergo major surgical operation before CAR-T treatment, surgical operation happened =4 weeks prior to enrollment, or did not be fully recovered and clinically stable prior to enrollment, or be anticipated to undergo major surgical operation during the study;

15. Any unstable cardiovascular diseases happened =6 months prior to enrollment, including but not limited to, unstable angina, myocardial infarction, heart failure (NYHA grade= III grade), severe arrhythmia that require drug interference, cardiac angioplasty/coronary stent implantation/ cardiac bypass surgery =6 months prior to enrollment;

16. Presence of central nervous system(CNS) disease or disease history, including epilepsy, cerebral Ischemia/bleeding, dementia, cerebellar disease, any autoimmune diseases that involve CNS;

17. Presence of active infection that require therapy =2 weeks prior to apheresis;

18. Any other conditions that researcher think it is inappropriate for the subject to anticipate the trial.

Related Conditions & MeSH terms

• B-cell Acute Lymphoblastic Leukemia
• Precursor Cell Lymphoblastic Leukemia-Lymphoma

Intervention

Biological:
• GC022F
GC022F is the CAR-T cell immunotherapy targeted CD19 and CD22. The subjects will receive GC022F as one dose. The dosage ranges from 6×10^4 to 1.5×10^5 CAR+T/Kg.

Locations

Country	Name	City	State
China	Hebei Yanda Ludaopei Hospital	Sanhe	Hebei

Sponsors (3)

Lead Sponsor	Collaborator
Hebei Yanda Ludaopei Hospital	Beijing Ludaopei Hospital, Gracell Biotechnology Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence and severity of treatment related Adverse Events, CRS and Neurotoxicity (Safety and tolerability)	Adverse events(AEs) will be collected and graded according to ASTCT consensus(for Cytokine Release Syndrome, CRS and Immune Effector Cell-Associated Neurotoxicity Syndrome, ICANS) and CTCAE v5.0(for AE except CRS/ICANS )	2 years
Secondary	CAR copies and concentration of GC022F in peripheral blood, bone marrow and CSF (amplification and persistence)	GC022F CAR copies and cells in peripheral blood, bone marrow and CSF will be measured by qPCR and FCM in 2 years	2 years
Secondary	Overall response rate of patients who received GC022F infusion (efficacy)	Overall response rate will be estimated as the percents of patients who achieved CR or CRi.	2 years
Secondary	Concentraiton of anti-GC022F antibody after infusion (humoral immune response)	After GC022F infusion, GC022F antibody in peripheral blood will be measured in 2 years	2 years